An investigation for investors in NASDAQ:SQNM shares was announced concerning whether the takeover of Sequenom, Inc. by Laboratory Corporation of America Holdings for $2.40 per share is unfair.
Investors who purchased shares of Sequenom, Inc. (NASDAQ:SQNM) and currently hold any of those NASDAQ:SQNM shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain directors of Sequenom, Inc.breached their fiduciary duties owed to NASDAQ:SQNM investors in connection with the proposed acquisition.
On July 27, 2016, Laboratory Corporation of America Holdings and Sequenom, Inc announced that they have entered into an agreement and plan of merger under which Laboratory Corporation of America Holdings would acquire all of the outstanding shares of Sequenom in a cash tender offer for $2.40 per share, or an equity value of $302 million, which represents a total enterprise value of approximately $371 million, including net indebtedness.
However, given that in 2015 NASDAQ:SQNM shares reached $4.59 per share, the investigation concerns whether the offer is unfair to NASDAQ:SQNM stockholders. More specifically, the investigation concerns whether the Sequenom Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders’ best interests in connection with the proposed sale.
On August 17, 2016, NASDAQ:SQNM shares closed at $2.36 per share.
Those who are current investors in NASDAQ:SQNM shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com